Ascendia

  MARKET NEWS

Bio-Rad Launches PTC Tempo 48/48 & PTC Tempo 384 Thermal Cyclers 
Investigational Treatment for Fragile X Syndrome Receives Rare Pediatric Disease Designation From FDA
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
bYoRNA & Dyadic Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
AcuraStem Enters Into License Agreement With Takeda to Advance PIKFYVE Therapeutics
Coya Therapeutics Licenses Exclusive Worldwide Rights to Exosome Engineering Technology From Carnegie Mellon University

  FEATURED EDITORIAL

]

  COMPANY PROFILE

The Health business of Lubrizol Life Science (LLS Health), in partnership with customers, advances solutions inspiring a healthier life. We specialize in helping clients from idea to execution by offering innovative polymers and excipients, as well as best-in-class contract development and manufacturing services. Our long history of polymer expertise and continued investment in research and manufacturing means we offer you and your customers a smooth and streamlined approach to innovative healthcare solutions. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evonik Strengthens Portfolio of Nanoparticle Technologies & Services for Parenteral Drug Delivery

Evonik Strengthens Portfolio of Nanoparticle Technologies & Services for Parenteral Drug Delivery

Evonik is strengthening its platform of parenteral drug delivery solutions with three new standard PLA-PEG di-block copolymers and a new nanoparticle formulation service using….

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 From Ongoing MYCHELANGELO I Trial

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 From Ongoing MYCHELANGELO I Trial

Omega Therapeutics, Inc. recently announced encouraging preliminary safety, tolerability, pharmacokinetic, and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO I study evaluating….

SOHM Announces Acquisition of ABBIE, a World-Class Gene-Editing Platform That Can Deliver Genetic Payloads Using Non-Viral Vectors

SOHM Announces Acquisition of ABBIE, a World-Class Gene-Editing Platform That Can Deliver Genetic Payloads Using Non-Viral Vectors

With this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023. The gene-editing market is expected to grow….

MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services 

MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services 

MilliporeSigma is the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and….

  WHITEPAPERS & WEBINARS

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

[adrotate banner=”2024″

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER - Improving API Solubility by Salt & Cocrystal Formation

WHITEPAPER - Improving API Solubility by Salt & Cocrystal Formation

Ensuring sufficient solubility is critical to the success of small molecule drugs. An active pharmaceutical ingredient (API) must be absorbed by the body and enter the systemic circulation to deliver the desired therapeutic effect. Many APIs, however, suffer from low …

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.

Considerations include the …

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing

Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for

…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 11 – Prefilled Syringes
October 18 – Injection Devices